Skip to main content
Bray Group

Ethos Partners LLP (“Ethos”), one of Europe’s most active lower mid-market investors, is pleased to announce their investment in Bray Group (“Bray” or the “Company”), a long-established UK manufacturer of medical products.

Founded in 1857, Bray began as a family business over a century ago. Today, it has grown into a leading manufacturer and supplier of medical products, specialising in caustics and pessaries. Bray operates through its three brands Avoca, Portia, and Bray Healthcare, serving approximately 400 customers across 35 international markets. The business operates from Faringdon, Oxfordshire.

Ethos’ investment, supported by Triple Point, facilitates the buyout of existing shareholders and will support Bray and its management team on their journey toward growth and further international expansion.

Ethos Partners is a private investment office established by private equity professionals to provide £3-10 million of supportive equity capital to established, ambitious companies in the UK and Europe.

Pascal Wittet, Partner at Ethos said: “We are delighted to be backing Sally and the management team at Bray during the business’ next phase of growth. The management team has ambitious plans and believes the business is well placed to drive growth internationally, building on their existing product range. The company has a well-established and market leading position which we look forward to developing further.”

Sally Naunton, CEO of Bray Group said: “We are delighted to be backed by Ethos and believe that our collective ambition and enthusiasm for Bray will result in an exciting future for our company. Our commitment to shining the spotlight on uncomplicated healthcare and connecting patients and clinicians with intuitive products remains unwavering.”

Ethos were advised by Present Value (M&A Advisor), HCR (Legal Advisor), HMT (Financial and Tax Due Diligence), Chris Roberts Associates (Debt Advisory,) Kroll (Tax), MoorPharm (Commercial), Pharmula (Regulatory Due Diligence), 21159 Pharma (Regulatory Due Diligence), and Confidas People (Management Due Diligence).

Management and vendors were advised by Andrew Waide Associates (M&A Advisor) and Gateley (Legal Advisor).